# psoriasis - minimax-m3

- Benchmark system: raw
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4054
- Completion tokens: 8765
- Reasoning tokens: 
- Total tokens: 12819
- API requests reported: 
- Elapsed seconds: 51.133
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: MiniMax

---
<think>Let me carefully analyze this transcriptomics dataset comparing psoriatic lesional skin versus normal control skin. I need to interpret these differentially expressed genes in a biologically meaningful, evidence-grounded manner.

Let me first organize the data:

**Upregulated genes** (positive log2FC):
1. IL36A (11.37) - IL-36 family cytokine
2. DEFB4A (11.18), DEFB4B (11.03) - β-defensins
3. SERPINB4 (9.12), PI3 (9.24), S100A7A (9.83), LCE3A (8.30), VNN3P (8.28) - antimicrobial/keratinocyte
4. S100A12 (8.33), S100A8 (7.73), S100A7 (7.09) - S100 alarmins
5. TCN1 (8.04) - transcobalamin
6. TMPRSS11D (7.75) - serine protease
7. IL19 (7.58) - IL-19 cytokine
8. SPRR2A (7.31), SPRR2B (6.38), SPRR2D (5.92), SPRR2E (3.99), SPRR2F (7.22), SPRR2G (4.75) - small proline rich proteins
9. SERPINB3 (6.74) - serpin
10. HEPHL1 (6.33) - metallo-oxidase
11. ADGRF1 (6.64) - adhesion GPCR
12. AKR1B10 (6.27), AKR1B15 (5.23) - aldo-keto reductases
13. CXCL13 (5.89) - chemokine
14. RHCG (5.29) - ammonium transporter
15. GDA (5.90) - guanidine deaminase
16. ENKUR (4.88) - ion channel
17. IL20 (5.67), IL26 (4.36) - cytokines
18. IL36G (5.68) - IL-36 cytokine
19. TNIP3 (7.28) - TNFAIP3 interacting protein
20. GPR15LG (5.52) - GPR15 ligand
21. DEFB103A (5.76), DEFB103B (5.75) - β-defensins
22. KLK13 (4.05) - kallikrein
23. KRT6A (4.30) - keratin
24. PLA2G4D (4.61), PLA2G4E (2.47) - phospholipases
25. WNT5A (2.53) - Wnt ligand
26. BTC (-4.30) - wait, this is negative, betacellulin
27. SLC6A14 (4.47) - amino acid transporter
28. CYP2W1 (-4.70) - cytochrome
29. HRH2 (3.27) - histamine receptor
30. FABP5 (3.64) - fatty acid binding protein
31. CDK5R1 (2.35)
32. ZC3H12A (3.85) - MCPIP1, RNase
33. HPSE (2.92) - heparanase
34. GJB2 (4.42), GJB6 (3.02) - connexins
35. LCE3D (5.31) - late cornified envelope
36. CD274 (3.44) - PD-L1
37. PRKCQ (2.88) - PKC theta
38. CXCR2 (2.70) - chemokine receptor
39. S100A7A (9.83) - already listed
40. IL36RN (3.01) - IL-36 receptor antagonist

**Downregulated genes** (negative log2FC):
- LOC107984452 (-6.25)
- BTC (-4.30) - betacellulin/ErbB ligand
- LOC105371988 (-4.10)
- CYP2W1 (-4.70)
- LINC02660 (-3.90)
- LOC107984005 (-4.27)
- SAPCD1 (-2.94)
- UGT3A2 (-4.59)
- WAKMAR1 (-5.63)
- SAPCD1-AS1 (-2.84)
- LOC105371569 (4.60) - positive

Wait, let me re-check. The user said genes are separated into upregulated and downregulated, but they didn't actually separate them in the table. Let me look again - actually, they did NOT separate them; they just provided the table with all genes. I need to separate them myself.

Let me identify the top significant genes and their patterns:

**Top upregulated genes** (log2FC > 5, very significant):
- IL36A (11.37) - IL-36α cytokine
- DEFB4B (11.03), DEFB4A (11.18) - β-defensin 4
- S100A7A (9.83) - S100 alarmin
- PI3 (9.24) - peptidase inhibitor 3/elafin
- SERPINB4 (9.12) - serpin B4
- TCN1 (8.04) - haptocorrin/transcobalamin
- S100A12 (8.33) - calgranulin C
- S100A8 (7.73) - calgranulin A
- TMPRSS11D (7.75)
- IL19 (7.58) - IL-19
- TNIP3 (7.28) - TNFAIP3 interacting protein 3
- SPRR2A (7.31), SPRR2F (7.22), SPRR3 (7.18)
- LCE3A (8.30)
- SERPINB3 (6.74)
- VNN3P (8.28) - pseudogene but expressed
- ADGRF1 (6.64)
- AKR1B10 (6.27)
- HEPHL1 (6.33)
- SPRR2B (6.38)
- GDA (5.90)
- CXCL13 (5.89)
- DEFB103A/B (5.75-5.76)
- IL36G (5.68)
- LCE3D (5.31)
- IL20 (5.67)
- RHCG (5.29)
- AKR1B15 (5.23)
- CERNA2 (5.40)
- IL26 (4.36) actually 4.36

Let me focus on the major biological themes. In psoriasis lesional skin transcriptomics, the classic signatures are:

1. **IL-17/IL-23 axis** - Th17 cytokines
2. **Keratinocyte hyperproliferation and abnormal differentiation** - KRT6A, SPRR2 family, LCE3 family
3. **Antimicrobial peptides** - DEFB4A/B, S100A7, S100A8, S100A12, PI3
4. **IL-36 cytokines** - IL36A, IL36G, IL36RN
5. **Chemokines** - CXCL13, CXCR2, GPR15LG
6. **Lipid mediators** - PLA2G4D, PLA2G4E, FABP5
7. **NF-κB regulators** - TNIP3, ZC3H12A
8. **Keratinocyte cornified envelope** - SPRRs, LCEs

Now let me categorize:

**Core biological programs:**

1. **Keratinocyte cornified envelope and barrier dysfunction** - SPRR2A/B/D/E/F/G, SPRR3, LCE3A, LCE3D, GJB2, GJB6, KRT6A, SERPINB3, SERPINB4 - this is highly upregulated. SPRR2 family is dramatically upregulated (6-7 log2FC).

2. **Antimicrobial peptide/alarmin response** - S100A7, S100A7A, S100A8, S100A12, DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3 (elafin) - the classic psoriatic AMP signature.

3. **IL-36 cytokine axis** - IL36A (11.37), IL36G (5.68), IL36RN (3.01), plus IL19, IL20, IL26 - the IL-36/IL-20 subfamily signature.

4. **Inflammatory chemokine/immune cell recruitment** - CXCL13, CXCR2, GPR15LG (ligand for GPR15), CD274 (PD-L1)

5. **NF-κB/TLR negative regulators** - TNIP3, ZC3H12A (MCPIP1) - negative feedback to inflammatory signaling

6. **Lipid metabolism** - PLA2G4D, PLA2G4E, FABP5, AKR1B10, AKR1B15 - possibly Th17-related

7. **Cell proliferation** - CDK5R1, CCNE1, RRM2 - cell cycle

8. **WNT signaling** - WNT5A (non-canonical)

Let me think about downregulated genes:
- BTC (betacellulin, -4.30) - ErbB ligand, normally involved in keratinocyte homeostasis
- CYP2W1 (-4.70)
- LOC genes - mostly uncharacterized
- WAKMAR1 (-5.63) - lncRNA involved in wound healing/keratinocyte?
- SAPCD1 (-2.94) - tumor suppressor
- UGT3A2 (-4.59)

Actually, the downregulated genes in this list are mostly uncharacterized or low fold changes. The dominant signal is upregulation.

**Key genes to highlight:**
- IL36A - the most strongly upregulated gene (11.37 log2FC), IL-36α is central to psoriatic inflammation
- DEFB4A/B - β-defensin 4, the classic psoriasis biomarker
- S100A7A, S100A7, S100A8, S100A12 - alarmin signature
- SPRR2 family - keratinocyte differentiation
- TNIP3 - NF-κB negative regulator (genetically associated with psoriasis)
- CXCL13 - B cell chemokine, related to lymphoid neogenesis in psoriasis
- IL19, IL20, IL26 - IL-10 family cytokines
- PLA2G4D - phospholipase, neutrophil marker in psoriasis
- CD274 (PD-L1) - immune checkpoint
- PRKCQ - PKCθ, T cell signaling

**Validation priorities:**

1. **IL-36 axis as therapeutic target** - mechanistic/therapeutic. There are already anti-IL-36R antibodies (spesolimab, imsidolimab) being tested.

2. **β-defensin/S100 alarmin signature as biomarker** - biomarker. Classic psoriasis signature.

3. **TNIP3 genetic/functional interaction with NF-κB** - this gene is in the psoriasis susceptibility locus (PSORS6) and interacts with A20/TNFAIP3.

4. **CXCL13-driven lymphoid-like structures** - mechanistic hypothesis about B cell/T cell recruitment.

5. **SPRR2/LCE3 barrier dysfunction** - mechanistic hypothesis about keratinocyte differentiation.

**Limitations:**
- Tissue composition: lesional skin has infiltrating immune cells (neutrophils, T cells, DCs) which contributes to immune gene signals
- Treatment exposure: patients may have been on systemic/topical treatments
- Disease severity, body site
- Cell type deconvolution not shown
- Bulk RNA-seq masks cell-type specific signals

Now let me structure this response. I should provide:

1. Overall biological interpretation
2. Core biological programs (max 5)
3. Key genes/interaction modules (max 10)
4. Validation priorities (max 5)
5. Evidence grounding
6. Limitations

Let me also be careful to differentiate upregulated vs downregulated genes and provide log2FC values for direction.

Looking more carefully at the downregulated:
- LOC107984452 (-6.25) - uncharacterized
- WAKMAR1 (-5.63) - lncRNA
- CYP2W1 (-4.70) - cytochrome P450
- UGT3A2 (-4.59) - UDP-glucuronosyltransferase
- LOC107984005 (-4.27)
- BTC (-4.30) - betacellulin (ErbB ligand)
- LOC105371988 (-4.10)
- LINC02660 (-3.90)
- SAPCD1 (-2.94) - suppressor APC domain containing
- SAPCD1-AS1 (-2.84) - antisense

Most downregulated genes are lncRNAs or uncharacterized. The notable protein-coding downregulated gene is BTC (betacellulin), which is an EGFR/ErbB ligand.

Note: Some genes I'm flagging: VNN3P is a pseudogene, LOC genes are mostly uncharacterized, so I should focus on the well-characterized protein-coding genes.

Let me draft the response now.

For evidence grounding, I should be specific:
- Direct evidence from input dataset: log2FC, P value, FDR
- Pathway/ontology: GO terms, KEGG, Reactome, Hallmark
- Disease-association: genetic associations, literature
- Tissue-specific: epidermal expression patterns

Let me also note specific GO/pathway annotations:
- SPRR2A/B/D/E/F/G → GO:0030280 cornified envelope, GO:0018149 peptide cross-linking
- LCE3A/D → cornified envelope (GO:0001533)
- S100A7/A8/A12 → GO:0050832 defense response
- DEFB4 → GO:0042742 defense response to bacterium
- IL36A/G → GO:0006954 inflammatory response, IL-17 signaling pathway
- KRT6A → GO:0008544 epidermis development
- CXCL13 → GO:0008009 chemokine activity, B cell chemotaxis
- GPR15LG → GO:0019221 cytokine-cytokine receptor interaction
- TNIP3 → GO:0007249 NF-kappaB signaling
- PLA2G4D → GO:0004623 phospholipase A2 activity
- WNT5A → GO:0016055 Wnt signaling pathway
- CDK5R1 → cell cycle
- CCNE1 → cell cycle
- RRM2 → DNA replication
- CD274 (PD-L1) → immune checkpoint
- PRKCQ → T cell signaling
- SERPINB3/B4 → serine protease inhibitor, peptidase inhibitor
- IL19, IL20, IL26 → IL-10 family cytokines
- BTC (down) → EGFR ligand
- CYP2W1 (down) → cytochrome P450, xenobiotic metabolism

The top pathways to consider:
- KEGG: Psoriasis (hsa05321)
- KEGG: IL-17 signaling pathway
- KEGG: Cytokine-cytokine receptor interaction
- Reactome: Cytokine signaling, Innate immune system, Keratinization
- GO: Cornified envelope, Inflammatory response, Defense response
- Hallmark: Inflammatory response, IL6/JAK/STAT3, IL2/STAT5, etc.

Let me now construct the response. The response should be comprehensive but not overly long. Let me organize it well.

Actually, I want to double check IL36RN - this is the IL-36 receptor antagonist, which is upregulated. That's interesting because it's supposed to dampen IL-36 signaling, but it's still upregulated as part of the inflammatory feedback.

Also worth noting:
- PRKCQ (PKCθ) - critical for T cell activation, NF-κB in T cells
- IL26 - Th17 cytokine with antimicrobial activity
- GPR15LG - ligand for GPR15, involved in T cell trafficking

The pattern strongly suggests:
1. Keratinocyte hyperproliferation/differentiation
2. Innate antimicrobial defense
3. IL-17/IL-36/Th17 inflammation
4. T cell recruitment (GPR15LG, CXCL13)
5. NF-κB feedback regulation

Now let me also consider what's NOT in the list that might be expected:
- No IL17A/F in top genes (they may be present but not as highly ranked)
- No IL23A in top list
- No STAT genes in top list
- No LCK, ZAP70 in top list

This suggests the dominant signals are from keratinocytes (SPRR, LCE, KRT6, S100, DEFB4) and infiltrating neutrophils (S100A8/A12, IL36A/G, PLA2G4D), with some T cell signals (PRKCQ, IL26, GPR15LG).

Let me finalize my response now. I'll make it well-organized with clear sections.

One more thought: The strongest single gene signal is IL36A (log2FC 11.37), which is consistent with literature showing IL-36 is one of the most highly upregulated cytokines in psoriasis. DEFB4A/B are also at the top, classic AMPs. The S100A7A is also dramatically upregulated.

Let me also note the interesting upregulation of:
- CD274 (PD-L1) - this has been reported in psoriatic skin
- HPSE (heparanase) - involved in tissue remodeling
- FABP5 - fatty acid binding, involved in lipid metabolism in keratinocytes
- AKR1B10/AKR1B15 - aldo-keto reductases, upregulated in psoriatic skin
- TCN1 - transcobalamin, secreted by granulocytes

I'll structure my response now. The response should be authoritative, well-supported, and clearly delineate evidence types and limitations.

Let me finalize the response structure:

1. Overall Biological Interpretation (concise overview)
2. Core Biological Programs (≤5)
   - For each: name, direction, supporting genes, pathway, explanation, evidence strength, limitations
3. Key Genes and Interaction Modules (≤10)
   - For each: direction, role in programs, interaction nature
4. Validation Priorities (≤5)
   - Each with category, justification, evidence, next step, classification
5. Evidence Grounding (cross-cutting)
6. Limitations and Alternative Explanations (≤5)

I'll aim for depth without excessive length. Let me write this now.</think>

# Transcriptomic Interpretation: Psoriatic Lesional Skin vs. Normal Skin

## 1. Overall Biological Interpretation

This dataset reflects a transcriptome dominated by a hyperplastic, inflamed, and antimicrobial-poised epidermis. The most striking signals fall into four coherent themes:

- **Hyperproliferative/dysdifferentiated keratinocytes**, evidenced by a coordinated induction of small proline-rich proteins (SPRR2A/B/D/E/F/G, SPRR3), late cornified envelope components (LCE3A, LCE3D), keratins (KRT6A), connexins (GJB2, GJB6), and cornified-envelope serpins (SERPINB3, SERPINB4, SERPINB13).
- **An IL-17/IL-36-driven inflammatory cytokine program**, with the IL-36 subfamily (IL36A at log2FC ≈ 11.4, IL36G, and IL36RN) ranking among the most strongly induced transcripts, alongside IL-19, IL-20, IL-26, and the alarmin/AMP triad (S100A7/A7A/A8/A12, DEFB4A/B, PI3/elafin, DEFB103A/B).
- **Leukocyte recruitment and lymphoid-like organization**, marked by CXCL13, CXCR2, GPR15LG, CD274 (PD-L1), and PLA2G4D.
- **NF-κB negative feedback and lipid-metabolic remodeling** via TNIP3, ZC3H12A (MCPIP1), PLA2G4D/E, FABP5, and AKR1B10/AKR1B15.

The downregulated arm is comparatively sparse in annotated protein-coding genes, with **BTC (betacellulin, log2FC ≈ −4.3)** — an EGFR/ErbB ligand supporting keratinocyte homeostasis — being the most biologically interpretable signal, together with CYP2W1, UGT3A2, and the lncRNA WAKMAR1. The asymmetry between up- and downregulation suggests that psoriasis, at the lesional transcriptional level, is principally a gain-of-function inflammatory/barrier phenotype rather than a loss of homeostatic programs.

---

## 2. Core Biological Programs

### Program 1 — IL-36 / IL-20-family cytokine axis (upregulated)
- **Direction:** Strongly upregulated.
- **Supporting genes:** IL36A (log2FC ≈ +11.4), IL36G (+5.7), IL36RN (+3.0), IL19 (+7.6), IL20 (+5.7), IL26 (+4.4).
- **Pathway mapping:** KEGG "Cytokine–cytokine receptor interaction" (hsa04060); Reactome "Interleukin-36 signaling"; Hallmark "Inflammatory response."
- **Interpretation:** The IL-36 subfamily is the single most disproportionately induced cytokine module. IL-36α/γ act on keratinocytes and DCs via IL-36R/MyD88/NF-κB and amplify IL-17/IL-23 responses, while IL-19/IL-20 signal through IL-20R and drive epidermal hyperplasia. The simultaneous induction of IL36RN is consistent with attempted negative feedback rather than dampened signaling.
- **Evidence strength:** High for direction; well-supported by multiple independent cytokine members and convergent published RNA-seq studies of psoriatic skin.
- **Limitations:** mRNA-level signal does not quantify processed/active IL-36; the dataset cannot distinguish bioactive IL-36 from its pro-form.

### Program 2 — Keratinocyte cornified-envelope/barrier remodeling (upregulated)
- **Direction:** Strongly upregulated.
- **Supporting genes:** SPRR2A/B/D/E/F/G, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6, SERPINB3, SERPINB4, SERPINB13, PI3, FABP5.
- **Pathway mapping:** GO:0018149 "peptide cross-linking"; GO:0001533 "cornified envelope"; Reactome "Keratinization"; KEGG "Epidermal keratinization-related cysteine-rich protein" cluster.
- **Interpretation:** The coordinate induction of SPRR2 paralogues (six paralogues with log2FC +4 to +7.3) is a hallmark of hyperplastic/dysregulated keratinocyte differentiation, not normal orthokeratosis. GJB2/GJB6 upregulation indicates altered gap-junction communication typical of wounded/hyperplastic epidermis. Loss of barrier function is reinforced by reduced BTC, an EGFR ligand that normally sustains epithelial homeostasis.
- **Evidence strength:** High for the hyperplastic differentiation phenotype; supported by an unusually broad SPRR/LCE/SERPIN module.
- **Limitations:** The SPRR2 induction is highly non-specific and can be induced by wounding, retinoids, or barrier disruption — its presence alone does not uniquely mark psoriasis.

### Program 3 — Antimicrobial peptide / alarmin program (upregulated)
- **Direction:** Strongly upregulated.
- **Supporting genes:** DEFB4A (+11.2), DEFB4B (+11.0), DEFB103A (+5.76), DEFB103B (+5.75), S100A7A (+9.8), S100A7 (+7.1), S100A8 (+7.7), S100A12 (+8.3), PI3/elafin (+9.2).
- **Pathway mapping:** GO:0042742 "defense response to bacterium"; GO:0050832 "defense response to fungus"; Reactome "Innate immune system"; Hallmark "Inflammatory response."
- **Interpretation:** The β-defensin 4 (DEFB4A/B) doublet is a classical IL-17A/IL-22 target and the single most established psoriatic AMP signature. S100A7/A7A/A8/A12 are neutrophil- and keratinocyte-derived alarmins that sustain feed-forward neutrophil recruitment via TLR4/RAGE. The fold-changes here (≥9) are among the largest in the entire transcriptome.
- **Evidence strength:** Very high — these genes are textbook IL-17/IL-22 readouts and are reproducibly the most upregulated transcripts in psoriatic epidermis.
- **Limitations:** Strongly cell-composition-dependent; infiltrating neutrophils and Th17 cells amplify these signals. Cannot be used to infer microbial involvement without functional studies.

### Program 4 — Leukocyte recruitment and T-cell costimulation (upregulated)
- **Direction:** Upregulated.
- **Supporting genes:** CXCL13 (+5.9), CXCR2 (+2.7), GPR15LG (+5.5), CD274/PD-L1 (+3.4), PRKCQ/PKCθ (+2.9), IL26 (+4.4), TCN1 (+8.0), PLA2G4D (+4.6), HPSE (+2.9).
- **Pathway mapping:** KEGG "Chemokine signaling" (hsa04062); GO:0008009 "chemokine activity"; Reactome "Interleukin-17 signaling"; GO:0007249 "NF-κB signaling."
- **Interpretation:** CXCL13 is the B-zone chemokine of ectopic lymphoid-like structures described in chronic plaques; GPR15LG (the ligand for GPR15) marks skin-homing effector T cells. PRKCQ is the canonical T-cell-enriched PKC isoform required for NF-κB/IL-2 induction. IL26 — a Th17/Th22 effector cytokine with direct antimicrobial activity — and PLA2G4D (a neutrophil/neutrophil-derived phospholipase recently characterized as a psoriatic itch/cutaneous inflammation driver) together mark active adaptive-innate crosstalk. Upregulation of CD274 suggests an induced local immune-checkpoint program.
- **Evidence strength:** Moderate-to-high for direction; module is biologically coherent but each gene alone carries limited diagnostic specificity.
- **Limitations:** Cell-type deconvolution is not possible from the input; the apparent "immune recruitment" signal may simply reflect greater immune-cell infiltration rather than a keratinocyte-intrinsic program.

### Program 5 — NF-κB negative-feedback and lipid remodeling (upregulated; BTC downregulated)
- **Direction:** Mostly upregulated; BTC downregulated.
- **Supporting genes:** TNIP3 (+7.3), ZC3H12A/MCPIP1 (+3.85), PLA2G4D (+4.6), PLA2G4E (+2.5), FABP5 (+3.6), AKR1B10 (+6.3), AKR1B15 (+5.2), IRAK2 (+2.08); BTC (−4.30).
- **Pathway mapping:** KEGG "NF-κB signaling pathway"; GO:0006629 "lipid metabolic process"; Reactome "Cytokine signaling in immune system."
- **Interpretation:** TNIP3 (also known as ABIN-3) is a cooperator of A20/TNFAIP3 that terminates NF-κB activation; its strong induction alongside TNFAIP3-pathway genes is a hallmark of inflamed psoriatic skin. ZC3H12A degrades IL-6/IL-12 mRNA. PLA2G4D/E release arachidonic acid driving eicosanoid production, while FABP5 and AKR1B10/15 reshape the epidermal lipidome (and, in the case of FABP5, supply ligands for PPARβ/δ-mediated hyperplasia). Reduced BTC removes an EGFR-axis brake on keratinocyte proliferation.
- **Evidence strength:** High for direction; module is well-supported by independent prior studies.
- **Limitations:** TNIP3 is itself a known PSORS susceptibility locus, so its induction may partially reflect genetic background rather than a reactive program. Co-expressed genes in this module are not necessarily co-regulated.

---

## 3. Key Genes / Interaction Modules

| Gene | Direction (log2FC) | Role in programs | Nature of relationships |
|------|-------------------|------------------|--------------------------|
| **IL36A** | +11.4 | Master driver of Program 1; amplifier of AMP/keratinocyte responses | **Regulatory** — induces DEFB4, S100A, SPRRs via keratinocyte IL-36R/MyD88/NF-κB; **pathway co-membership** with IL36G and IL36RN. |
| **DEFB4A/B** | +11.2/+11.0 | Flags Program 3; direct IL-17/IL-22 transcriptional readout in keratinocytes | **Regulatory** targets of IL-17A/IL-22 via Act1/C/EBPβ; **co-expression** with S100A7/PI3 (correlated in multiple psoriatic datasets). |
| **S100A7A / S100A7 / S100A8 / S100A12** | +9.8 / +7.1 / +7.7 / +8.3 | Alarmin module of Program 3; also feeds Program 4 (neutrophil recruitment) | **Co-expression** cluster; S100A8/A12 form heterodimer calprotectin (**physical interaction** at protein level, though this is independent of transcript co-regulation). |
| **TNIP3** | +7.3 | NF-κB feedback hub (Program 5); sits within PSORS6 susceptibility locus | **Regulatory** — physically cooperates with A20/TNFAIP3 to terminate NF-κB; **genetic/clinical evidence** of psoriasis association. |
| **CXCL13** | +5.9 | Marks ectopic lymphoid-like structures (Program 4) | **Co-expression** with CD274 and infiltrating T-cell transcripts; **regulatory** induction by LTα/IL-22 in chronic inflammation. |
| **SPRR2A/B/D/E/F/G** | +7.3 / +6.4 / +5.9 / +4.0 / +7.2 / +4.8 | Keratinocyte differentiation module (Program 2) | **Co-expression** cluster; **pathway co-membership** in cornified envelope (Reactome: R-HSA-6809371); no direct physical interaction among them. |
| **GPR15LG** | +5.5 | Skin-homing T-cell chemokine (Program 4) | **Receptor–ligand** (physical ligand–receptor interaction with GPR15 on T cells); **co-expression** with PRKCQ. |
| **PLA2G4D** | +4.6 | Neutrophil/Th17 effector of Programs 4 & 5 | **Co-expression** with PLA2G4E (paralogous enzyme); **regulatory** induction by IL-17/IL-36. No direct interaction with PLA2G4E. |
| **CD274 (PD-L1)** | +3.4 | Inducible immune checkpoint (Program 4) | **Co-expression** with IFN-γ–driven genes; **regulatory** induction by IFN-γ/IL-17 — but no direct physical interaction implied. |
| **BTC** | −4.3 | Counter-program (loss of EGFR homeostasis) | **Pathway co-membership** with EGFR ligands; **regulatory** — its loss removes an EGFR-driven brake on keratinocyte proliferation. |

Interaction relationships explicitly **distinguished**: physical interactions are limited to well-established protein-level bindings (e.g., S100A8/A12 heterodimer, GPR15LG–GPR15 ligand-receptor). Most other relationships in this list are **regulatory** (transcriptional induction) or **co-expression/pathway co-membership**, not direct physical interaction.

---

## 4. Validation Priorities

### Priority 1 — IL-36 as a master amplifier of psoriatic keratinocyte responses
- **Category:** Mechanistic hypothesis / Therapeutic target.
- **Evidence in dataset:** IL36A is the single most strongly induced cytokine (log2FC +11.4); IL36G, IL36RN and downstream IL-36 targets (DEFB4, S100A7, SPRR2) are coordinately upregulated.
- **External evidence:** Spesolimab (anti-IL-36R) reduces pustular psoriasis flares; imsidolimab is in trials. IL-36γ transgenic mice develop psoriasiform dermatitis.
- **Next step:** Stratify lesional biopsies by IL36A expression and test whether IL36A-high lesions are preferentially responsive to IL-36 blockade; assess whether keratinocyte IL-36R blockade reduces DEFB4/S100A7 induction ex vivo.
- **Classification:** **Supported hypothesis** (the dataset confirms the cytokine module; causality requires perturbation).

### Priority 2 — DEFB4/S100A7 axis as a quantitative biomarker of IL-17/IL-22 pathway activity
- **Category:** Biomarker.
- **Evidence in dataset:** DEFB4A/B are top-ranked (log2FC +11), S100A7/A7A/A8/A12 cluster together (log2FC +7 to +9.8).
- **External evidence:** Multiple studies correlate DEFB4 expression with histological and clinical PASI scores; the S100/DEFB4 cassette is the most replicated molecular signature of plaque psoriasis.
- **Next step:** Test the AMP cassette (DEFB4 + S100A7 + PI3) as a non-invasive tape-strip biomarker that tracks disease activity and treatment response.
- **Classification:** **Established evidence** for the signature's association with psoriatic skin.

### Priority 3 — TNIP3 as a susceptibility-and-feedback hub linking genetics to disease activity
- **Category:** Interaction/network hypothesis / Mechanistic.
- **Evidence in dataset:** TNIP3 is the most strongly induced NF-κB feedback gene (log2FC +7.3) and sits in the PSORS6 risk locus.
- **External evidence:** TNIP3 variants are GWAS-associated with psoriasis; TNIP3 protein cooperates with A20/TNFAIP3 to terminate NF-κB signaling.
- **Next step:** Test whether TNIP3 risk alleles produce lower TNIP3 induction in patient keratinocytes, leading to sustained NF-κB activity; perform ChIP-seq for NF-κB binding to the TNIP3 promoter in psoriatic vs. normal keratinocytes.
- **Classification:** **Supported hypothesis**.

### Priority 4 — CXCL13/GPR15LG-driven lymphoid-like micro-organization in chronic plaques
- **Category:** Mechanistic hypothesis.
- **Evidence in dataset:** CXCL13 (+5.9), GPR15LG (+5.5), CD274 (+3.4) — a coherent module linking B-zone chemotaxis, skin-homing T-cell recruitment, and induced immune checkpoints.
- **External evidence:** CXCL13-expressing cells mark ectopic lymphoid-like aggregates in chronic psoriatic plaques; GPR15+ T cells are enriched in psoriatic skin.
- **Next step:** Immunofluorescence co-staining of CXCL13+ stromal cells, GPR15+ T cells, and B cells in lesional biopsies; correlate density with chronicity.
- **Classification:** **Exploratory hypothesis**.

### Priority 5 — Tissue-composition and cell-type-deconvolution check
- **Category:** Confounding / composition check.
- **Evidence in dataset:** Many "immune" transcripts (CXCL13, CXCR2, PLA2G4D, IL26, TCN1) may reflect infiltrating neutrophils and T cells rather than keratinocyte-intrinsic signaling.
- **External evidence:** Standard psoriatic lesional biopsies contain variable numbers of neutrophils (Munro microabscesses) and T cells.
- **Next step:** Run deconvolution (e.g., CIBERSORTx, EPIC, or scRNA-seq reference mapping) on the same dataset to partition signals into keratinocyte vs. neutrophil/T-cell compartments before drawing mechanistic conclusions.
- **Classification:** **Necessary methodological check** before any causal interpretation.

---

## 5. Evidence Grounding

- **Direct dataset evidence:** All fold-change, P-value, and FDR claims above are read directly from the supplied table. No external numeric value is reported.
- **Pathway/ontology evidence:** GO terms and KEGG/Reactome pathways cited are standard community annotations; e.g., SPRR2A → GO:0030280 cornified envelope; PLA2G4D → GO:0004623 phospholipase A2; CXCL13 → GO:0008009 chemokine activity. These are independent of the differential-expression analysis itself.
- **Protein-interaction/regulatory evidence:** IL-36 signaling pathway (Reactome R-HSA-9014823), S100A8/A12 heterodimer formation (UniCurtain/PDB-level evidence, not from this dataset), GPR15LG–GPR15 ligand–receptor pair. These constitute **independent** evidence relative to transcript co-expression.
- **Genetic/clinical evidence:** TNIP3 is mapped to the PSORS6 psoriasis susceptibility locus; GWAS association is independent of any expression observation here. The IL-36 / DEFB4 / S100A7 modules are also supported by multiple published psoriatic transcriptomes; the current dataset is therefore **confirmatory** rather than independent discovery.
- **Drug/therapeutic evidence:** Spesolimab, imsidolimab (anti-IL-36R) clinical data exist; these are independent from the dataset. The mere existence of a drug does not validate the gene as a target in this tissue, and I have not used it as such.
- **Convergence vs. independence:** Most supporting evidence (GWAS + published transcriptomes + clinical trials) overlaps with each other and with prior psoriasis literature; genuinely independent evidence would come from mechanistic perturbation (CRISPR, blocking antibodies) and from non-overlapping cohorts, which are not present in this input.

Where evidence is thin (e.g., CXCL13 lymphoid neogenesis), I have explicitly labeled the claim as exploratory.

---

## 6. Limitations and Alternative Explanations

1. **Cell-composition confounding.** Lesional biopsies contain infiltrating neutrophils, T cells, and DCs. Genes such as S100A8/A12, IL36A/G, PLA2G4D, CXCL13, TCN1, and IL26 are likely **partly or substantially neutrophil- or T-cell-derived** rather than keratinocyte-intrinsic. Mitigated by deconvolution (Priority 5) and validated by scRNA-seq.

2. **Treatment exposure.** Topical steroids, vitamin D analogues, methotrexate, or biologics prior to biopsy would dampen cytokine signals (IL-17/IL-23 downstream transcripts) without proportionally reducing structural keratinocyte markers, biasing toward barrier/differentiation programs. Mitigated by recording treatment status at sampling and analyzing treatment-naïve subsets.

3. **Disease severity, body site, and chronicity.** PASI, lesion age (early vs. chronic), and acral vs. trunk location all influence the relative weight of IL-36 vs. IL-17/IL-22 vs. IL-23 programs. The dataset does not stratify by these covariates.

4. **Non-specific pathway enrichment.** Many of the most strongly upregulated genes (SPRR2A/B/D/E/F/G, LCE3A/D, KRT6A, S100A7/PI3) are also induced by wounding, retinoids, and other epidermal stresses; their co-induction here is **necessary but not specific** to psoriasis.

5. **Association-versus-causation ambiguity.** The cross-sectional design cannot establish whether IL36A → DEFB4, CXCL13 → ectopic lymphoid structures, or TNIP3 → sustained NF-κB are causal arrows. None should be presented as established mechanistic relationships without perturbation data.

6. **Sparse downregulated arm.** Most negative-log2FC entries are uncharacterized lncRNAs/pseudogenes (LOC105371988, LOC107984452, WAKMAR1, SAPCD1-AS1) or unstudied enzymes (CYP2W1, UGT3A2). BTC is the only downregulated protein-coding gene with a clear psoriasis-relevant function (EGFR-axis maintenance), so the dataset is **strongly biased toward detecting gain-of-function inflammation/barrier programs** rather than loss-of-homeostasis programs.

7. **Bulk-RNA masking of cell-type-specific signals.** Without single-cell or spatial data, "gene X is upregulated" cannot be attributed to a specific cellular compartment; this is the single largest interpretive caveat for downstream hypotheses.
